Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic IPO Marketing Expected to Start in Mid-October 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Add as a preferred source on Google
SAN DIEGO, March 01, 2018 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results for the fourth quarter and full year 2017 as well as provide a corporate update at 4:30 p.m. EST on March 8, 2018.
The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 1898244. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for otology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
[email protected]
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]
